Sanofi’s $16 Billion Consumer Healthcare Sale Raises Accessibility Concerns Amid French Government Intervention

Kirkland & Ellis, Freshfields Bruckhaus Deringer, and Bredin Prat are advising on Sanofi’s potential sale of its consumer healthcare unit to a U.S. private equity fund. This deal, potentially valued at $16 billion, has sparked controversy. Critics are voicing concerns regarding how a non-domestic purchaser might affect medication accessibility in France. In response to these apprehensions, the French government has agreed to buy a minority stake to mitigate the impact. For further details, the original article can be accessed here.